Julie Forman-Kay is program head in molecular medicine at the Hospital for Sick Children in Toronto, Canada. She received her B.Sc. in chemistry from the Massachusetts Institute of Technology and her Ph.D. in molecular biophysics andd biochemistry from Yale University. The major focus of her lab is to provide biological insights into how dynamic properties of proteins are related to function and methodological tools to enable better understanding of dynamic and disordered states. Most recently, her lab has probed the biophysics of protein phase separation and how it regulates cellular condensates and biological function.
Julie Forman-Kay
Program head
Hospital for Sick Children
From this contributor
How microscopic ‘condensates’ in cells might contribute to autism
A controversial idea about how cells compartmentalize their contents into droplets — like beads of oil in water — could be key to understanding autism, says Julie Forman-Kay.
How microscopic ‘condensates’ in cells might contribute to autism
By
Angie Voyles Askham
23 February 2021 | 7 min read
Explore more from The Transmitter
Infant Brain Imaging Study findings, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 23 March.
Infant Brain Imaging Study findings, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 23 March.
By
Jill Adams
24 March 2026 | 2 min read
Trading places: What happens when neuroscience turns into machine learning, and machine learning turns into neuroscience?
Neuroscience has become increasingly concerned with prediction, and machine learning with causal explanation, with each field adopting methods from the other. I asked eight experts to weigh in on what we stand to learn from this exchange.
Trading places: What happens when neuroscience turns into machine learning, and machine learning turns into neuroscience?
Neuroscience has become increasingly concerned with prediction, and machine learning with causal explanation, with each field adopting methods from the other. I asked eight experts to weigh in on what we stand to learn from this exchange.
By
Samuel Gershman
23 March 2026 | 22 min read
Exon-skipping approach boosts levels of key Rett syndrome protein
Deleting a small region of the MECP2 gene partially restored function in neurons derived from people with Rett-associated variants.
Exon-skipping approach boosts levels of key Rett syndrome protein
Deleting a small region of the MECP2 gene partially restored function in neurons derived from people with Rett-associated variants.
By
Giorgia Guglielmi
20 March 2026 | 5 min read